@article {Anderson:August 2006:1465-6566:1475,
	author = "Anderson, Pete",
	title = "Samarium for osteoblastic bone metastases and osteosarcoma",
	journal = "Expert Opinion on Pharmacotherapy",
	volume = "7",
	year = "August 2006",
	abstract = "Samarium-153 lexidronam (<SUP>153</SUP>Sm-EDTMP) is FDA approved for painful osteoblastic bone metastases that image on bone scan. <SUP>153</SUP>Sm-EDTMP decay has a therapeutic &#946;-emission and a &#947;-photon for bone scan imaging. Monitoring of osteosarcoma radiation treatment effectiveness was performed with bone, CT, MRI and PET/CT fusion imaging. Bone scan and PET/CT improved in 5 out of 9 and 16 out of 18 osteosarcoma sites, respectively. <SUP>153</SUP>Sm-EDTMP targets multiple sites of disease, with a single administration. Side effects of <SUP>153</SUP>Sm-EDTMP (0.5 - 2.5 mCi/kg) have been minimal and include transient thrombocytopenia and neutropenia. <SUP>153</SUP>Sm-EDTMP can be combined with radiation therapy, bisphosphonates and/or chemotherapy to synergistically improve palliation. This article reviews the rationale, indications and monitoring of standard-dose samarium and investigational high-dose <SUP>153</SUP>Sm-EDTMP treatment of cancer involving bone.",
	pages = "1475-1486(12)",
	url = "http://www.ingentaconnect.com/content/apl/eop/2006/00000007/00000011/art00007"
	doi = "doi:10.1517/14656566.7.11.1475"
}